drugset / Trial / NCT01004081
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of 2 dosing regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had progressed following treatment with a nonsteroidal aromatase inhibitor (AI).
Timeline
- Start
- 2009-11
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIIB021 | Small molecule | 100 mg | Oral |
| Subject | BIIB021 | Small molecule | 450 mg | Oral |
| Background | Exemestane | Small molecule | 25 mg | — |